![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Westphalen, C.B. 
ORCID: https://orcid.org/0000-0002-5310-3754; Martins-Branco, D. ORCID: https://orcid.org/0000-0002-7214-4818; Beal, J.R. ORCID: https://orcid.org/0000-0001-8898-0549; Cardone, C.; Coleman, N.; Schram, A.M.; Halabi, S.; Michiels, S. ORCID: https://orcid.org/0000-0002-6963-2968; Yap, C. ORCID: https://orcid.org/0000-0002-6715-2514; André, F.; Bibeau, F.; Curigliano, G. ORCID: https://orcid.org/0000-0003-1781-2518; Garralda, E. ORCID: https://orcid.org/0000-0002-4412-7842; Kummar, S.; Kurzrock, R. ORCID: https://orcid.org/0000-0003-4110-1214; Limaye, S.; Loges, S.; Marabelle, A. ORCID: https://orcid.org/0000-0002-5816-3019; Marchió, C.; Mateo, J.; Rodon, J. ORCID: https://orcid.org/0000-0001-6467-3632; Spanic, T.; Pentheroudakis, G. ORCID: https://orcid.org/0000-0002-6632-2462 und Subbiah, V. ORCID: https://orcid.org/0000-0002-6064-6837
(2024):
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.
In: Annals of Oncology, Bd. 35, Nr. 11: S. 936-953
[PDF, 2MB]
ORCID: https://orcid.org/0000-0002-5310-3754; Martins-Branco, D. ORCID: https://orcid.org/0000-0002-7214-4818; Beal, J.R. ORCID: https://orcid.org/0000-0001-8898-0549; Cardone, C.; Coleman, N.; Schram, A.M.; Halabi, S.; Michiels, S. ORCID: https://orcid.org/0000-0002-6963-2968; Yap, C. ORCID: https://orcid.org/0000-0002-6715-2514; André, F.; Bibeau, F.; Curigliano, G. ORCID: https://orcid.org/0000-0003-1781-2518; Garralda, E. ORCID: https://orcid.org/0000-0002-4412-7842; Kummar, S.; Kurzrock, R. ORCID: https://orcid.org/0000-0003-4110-1214; Limaye, S.; Loges, S.; Marabelle, A. ORCID: https://orcid.org/0000-0002-5816-3019; Marchió, C.; Mateo, J.; Rodon, J. ORCID: https://orcid.org/0000-0001-6467-3632; Spanic, T.; Pentheroudakis, G. ORCID: https://orcid.org/0000-0002-6632-2462 und Subbiah, V. ORCID: https://orcid.org/0000-0002-6064-6837
(2024):
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development.
In: Annals of Oncology, Bd. 35, Nr. 11: S. 936-953
[PDF, 2MB]
Janning, M.; Sueptitz, J.; Albers-Leischner, C.; Delpy, P.; Tufman, Amanda; Velthaus-Rusik, J.-L.; Reck, M.; Jung, A.; Kauffmann-Guerrero, Diego ORCID: https://orcid.org/0000-0003-1471-3290; Bonzheim, I.; Braendlein, S.; Hummel, H.-D.; Wiesweg, M.; Schildhaus, H.-U.; Stratmann, J. A.; Sebastian, M.; Alt, J.; Buth, J.; Esposito, I.; Berger, J.; Toegel, L.; Saalfeld, F. C.; Wermke, M.; Merkelbach-Bruse, S.; Hillmer, A. M.; Klauschen, F.; Bokemeyer, C.; Buettner, R.; Wolf, J. und Loges, S.
(2022):
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM).
In: Annals of Oncology, Bd. 33, Nr. 6: S. 602-615
ORCID: https://orcid.org/0000-0003-1471-3290; Bonzheim, I.; Braendlein, S.; Hummel, H.-D.; Wiesweg, M.; Schildhaus, H.-U.; Stratmann, J. A.; Sebastian, M.; Alt, J.; Buth, J.; Esposito, I.; Berger, J.; Toegel, L.; Saalfeld, F. C.; Wermke, M.; Merkelbach-Bruse, S.; Hillmer, A. M.; Klauschen, F.; Bokemeyer, C.; Buettner, R.; Wolf, J. und Loges, S.
(2022):
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM).
In: Annals of Oncology, Bd. 33, Nr. 6: S. 602-615
Janning, M.; Müller, V; Vettorazzi, E.; Cubas-Cordova, M.; Gensch, V; Ben Batalla, I; Eulenburg, C. zu; Schem, C.; Fasching, P. A.; Schnappauf, B.; Karn, T.; Fehm, T.; Just, M.; Kühn, T.; Holms, F.; Overkamp, F.; Krabisch, P.; Rack, B.; Denkert, C.; Untch, M.; Tesch, H.; Rezai, M.; Kittel, K.; Pantel, K.; Bokemeyer, C.; Loibl, S.; Minckwitz, G. von und Loges, S.
(2016):
Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
In: Oncology Research and Treatment, Bd. 39: S. 185